Alembic announces successful USFDA inspection at joint venture
Aleor Dermaceuticals Ltd., a 60:40 joint venture between Alembic Pharmaceuticals Ltd. and Orbicular Pharmaceutical Technologies Pvt. Ltd., has successfully cleared its first US FDA inspection of its new formulation facility located at Karakhadi, Gujarat, without any observations. The scheduled inspection was carried out between October 15-19, 2018.
Aleor was formed in April 2016 to develop, manufacture and commercialise dermatology products for worldwide markets. Till date the company has filed six ANDAs.
“This is a result of the dedication, commitment and focus of the entire Aleor team to ensure highest quality standards are maintained and we are very excited to build this organisation on a global platform,” said Dr. M.S. Mohan, Founder and Managing Director of Orbicular.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-08-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
关于进一步规范化学品信息发布、加强全球管制目录宣导的公告 Announcement on Further Standardizing the Release of Chemical Information and Strengthening Public Awareness of Global Control Lists
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%
-
关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI
-
FDA Fast-Tracks U.S. Drug Manufacturing
-
FDA Warning Letters Put GMP Back in Focus
-
Pesticide Market in Limbo: Prices Plunge Amid Weak Demand and Overcapacity—Only a Few Hold Firm
Recommend Reading
-
![Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants]()
Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants
-
![Glyphosate Faces New UK Pressure as EU Trade Alignment Returns to the Debate]()
Glyphosate Faces New UK Pressure as EU Trade Alignment Returns to the Debate
-
![FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance]()
FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance
-
![Brazil Expands Chemical Tax Breaks as India’s Crop Protection Industry Warns of a 25% Cost Increase]()
Brazil Expands Chemical Tax Breaks as India’s Crop Protection Industry Warns of a 25% Cost Increase
-
![After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition]()
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
![Business Society’s Market Outlook for MIBK on August 18, 2026: Volatile and Tending to Weaken]()
Business Society’s Market Outlook for MIBK on August 18, 2026: Volatile and Tending to Weaken
-
![Business Society’s Market Outlook for Hydrogen Peroxide on August 17, 2026: Bearish]()
Business Society’s Market Outlook for Hydrogen Peroxide on August 17, 2026: Bearish
-
![Business Society’s PVC Market Outlook on August 18, 2026: Upward Trend]()
Business Society’s PVC Market Outlook on August 18, 2026: Upward Trend
-
![Business Society’s Market Outlook for Caustic Soda on August 17, 2026: Narrow-Range Fluctuations]()
Business Society’s Market Outlook for Caustic Soda on August 17, 2026: Narrow-Range Fluctuations
-
![Both Cost and Demand Weighing Down PTA Prices, Leading to Volatile Declines]()
Both Cost and Demand Weighing Down PTA Prices, Leading to Volatile Declines
